Compare Novavax Inc (NVAX) vs ON Holding AG (ONON) Price & Performance

Novavax (NVAX) trades at $7.89, down 0.75% on the day, with a bullish technical signal despite mixed indicators. The company reported a strong Q2 2026 earnings beat, raising its full-year revenue outlook, while maintaining a low valuation with a P/E of 3.14 and EV/EBITDA of 1.72. However, negative net income margin and shareholder equity highlight financial challenges.

The outlook is cautiously optimistic, driven by partnership milestones with Sanofi and cost reductions, but risks include persistent cash burn and competitive vaccine market pressures. Analyst consensus leans bullish with 74% buy ratings, suggesting potential upside if execution improves.

ONON shares plunged 19.52% to $31.21 after Q2 2026 earnings revealed a rare revenue miss and reduced full-year growth guidance, despite beating EPS estimates. The stock now trades near key support at $30 with bearish technical indicators dominating. Fundamentally, the company maintains strong profitability with 64.82% gross margins and 23.95% ROE, but wholesale channel weakness and cautious consumer spending have tempered growth expectations.

While current valuation multiples appear reasonable (P/E 21.17, P/S 5), the stock faces near-term headwinds from growth deceleration. Analyst consensus remains bullish with a $52.86 price target representing 69% upside, but investors should monitor Q3 earnings execution and wholesale recovery for confirmation of the investment thesis.